Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of hypofractionated radiotherapy plus PD-1/PD-L1 inhibitor and GM-CSF in advanced metastatic solid tumors
ChiCTR1900026175Phase 2Recruiting
- Sponsor
- The Second Affiliated Hospital of Soochow University
- Start
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in Nonhematologic neoplasms, sponsored by The Second Affiliated Hospital of Soochow University. Primary endpoint: objective response rate. Started Mar 2019; status: recruiting.
02
Drugs
sargramostim
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR1900026175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026175.